PLK1expression and BI 2536 effects in childhood acute lymphoblastic leukemia

In vitro targeting of Polo-like kinase 1 in bladder carcinoma

(2013) María Sol Brassesco et al.   CANCER BIOLOGY & THERAPY

Polo-like kinase 1 inhibition causes decreased proliferation by cell cycle arrest, leading to cell death in glioblastoma

(2013) J A Pezuk et al.   CANCER GENE THERAPY

The expression of Nek7, FoxM1, and Plk1 in gallbladder cancer and their relationships to clinicopathologic features and survival

(2013) R. Wang et al.   Clinical & Translational Oncology

Polo-like kinase 1 is overexpressed in colorectal cancer and participates in the migration and invasion of colorectal cancer cells

(2013) Ding-pei Han et al.   MEDICAL SCIENCE MONITOR

BCL-2 Hypermethylation Is a Potential Biomarker of Sensitivity to Antimitotic Chemotherapy in Endocrine-Resistant Breast Cancer

(2013) A. Stone et al.   MOLECULAR CANCER THERAPEUTICS

Initial testing (stage 1) of the polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program

(2013) Richard Gorlick et al.   PEDIATRIC BLOOD & CANCER

Polo-like kinase 1 is overexpressed in renal cancer and participates in the proliferation and invasion of renal cancer cells

(2013) Guojun Zhang et al.   TUMOR BIOLOGY

Clinicopathological significance of Polo-like kinase 1 (PLK1) expression in human malignant glioma

(2011) Mao-Wei Cheng et al.   ACTA HISTOCHEMICA

An in-vitro evaluation of the polo-like kinase inhibitor GW843682X against paediatric malignancies

(2011) Kristina Spaniol et al.   ANTI-CANCER DRUGS

Polo-like Kinase 1 Inhibitors and Their Potential Role in Anticancer Therapy, with a Focus on NSCLC

(2011) R. H. Medema et al.   CLINICAL CANCER RESEARCH

PLK1 as an oncology target: current status and future potential

(2011) Campbell McInnes et al.   DRUG DISCOVERY TODAY

Expression, adverse prognostic significance and therapeutic small molecule inhibition of Polo-like kinase 1 in multiple myeloma

(2011) Robert P. Evans et al.   LEUKEMIA RESEARCH

High expression of polo-like kinase 1 is associated with the metastasis and recurrence in urothelial carcinoma of bladder

(2011) Zhe Zhang et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Polo-like kinase 1 (Plk1) in non-melanoma skin cancers

(2010) Travis Schmit et al.   CELL CYCLE

An Open-Label, Phase I Study of the Polo-like Kinase-1 Inhibitor, BI 2536, in Patients with Advanced Solid Tumors

(2010) R.-D. Hofheinz et al.   CLINICAL CANCER RESEARCH

Benefits of the Intermittent Use of 6-Mercaptopurine and Methotrexate in Maintenance Treatment for Low-Risk Acute Lymphoblastic Leukemia in Children: Randomized Trial From the Brazilian Childhood Cooperative Group—Protocol ALL-99

(2010) Silvia R. Brandalise et al.   JOURNAL OF CLINICAL ONCOLOGY

Recent Research Advances in Childhood Acute Lymphoblastic Leukemia

(2010) Ching-Hon Pui   JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION

Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy

(2010) Klaus Strebhardt   NATURE REVIEWS DRUG DISCOVERY

A simplified minimal residual disease polymerase chain reaction method at early treatment points can stratify children with acute lymphoblastic leukemia into good and poor outcome groups

(2009) C. A. Scrideli et al.   HAEMATOLOGICA

Targeted Depletion of Polo-Like Kinase (Plk) 1 Through Lentiviral shRNA or a Small-Molecule Inhibitor Causes Mitotic Catastrophe and Induction of Apoptosis in Human Melanoma Cells

(2009) Travis L. Schmit et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

A novel treatment strategy targeting polo-like kinase 1 in hematological malignancies

(2009) T Ikezoe et al.   LEUKEMIA

Polo-Like Kinase (PLK) Inhibitors in Preclinical and Early Clinical Development in Oncology

(2009) P. Schoffski   ONCOLOGIST

Overexpression of polo-like kinase1 predicts a poor prognosis in hepatocellular carcinoma patients

(2009) Zi-Li He et al.   WORLD JOURNAL OF GASTROENTEROLOGY